Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of Bimekizumab in active nonradiographic axial spondyloarthritis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonradiographic Axial Spondyloarthritis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Nonradiographic Axial Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2024-11-13